GSK (LON:GSK) Stock Rating Reaffirmed by Barclays

GSK (LON:GSK)‘s stock had its “equal weight” rating restated by analysts at Barclays in a research report issued to clients and investors on Tuesday, MarketBeat reports. They presently have a GBX 1,725 ($21.67) target price on the stock. Barclays‘s price target would indicate a potential downside of 2.73% from the stock’s current price.

A number of other research firms have also weighed in on GSK. JPMorgan Chase & Co. raised their price objective on shares of GSK from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) and gave the company an “underweight” rating in a research note on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,950 ($24.50) price target on shares of GSK in a report on Wednesday, April 17th. Shore Capital reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, May 1st. Finally, Berenberg Bank raised their price target on shares of GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the company a “buy” rating in a report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, GSK currently has an average rating of “Hold” and a consensus price target of GBX 1,675.63 ($21.05).

GSK Stock Up 0.7 %

LON:GSK opened at GBX 1,773.50 ($22.28) on Tuesday. The firm has a market cap of £72.54 billion, a P/E ratio of 1,477.92, a P/E/G ratio of 1.12 and a beta of 0.27. The company has a debt-to-equity ratio of 140.82, a quick ratio of 0.73 and a current ratio of 0.88. GSK has a fifty-two week low of GBX 1,302.60 ($16.36) and a fifty-two week high of GBX 1,776 ($22.31). The firm has a 50-day simple moving average of GBX 1,666.29 and a two-hundred day simple moving average of GBX 1,562.88.

Insider Buying and Selling

In other GSK news, insider Urs Rohner acquired 434 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The shares were bought at an average price of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,061.66). In other news, insider Urs Rohner purchased 434 shares of the stock in a transaction on Wednesday, March 20th. The shares were acquired at an average price of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,061.66). Also, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total transaction of £2,317,751.36 ($2,911,747.94). 1.77% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.